Metabolic surgery in patients with diabesity: A review of the historical backgrounds and scoring systems
More details
Hide details
Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAUDI ARABIA
Department of Physiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAUDI ARABIA
Publication date: 2024-01-03
Electron J Gen Med 2024;21(1):em564
Diabesity is a modern term that describes the coexistence of adverse health effects of diabetes mellitus and obesity and indicates a causal pathophysiological relationship between the two phenomena. The progression of diabesity leads to a deterioration of multiple organs and systems. Effective intervention for patients with diabesity must include optimal obesity therapy to prevent secondary complications. Metabolic surgery is the most effective and sustainable therapy for severe obesity and the elimination or prevention of many associated diseases, including type 2 diabetes mellitus, hypertension, sleep apnea, heart disease, and certain cancers. This review provides an up-to-date overview of surgical interventions for obesity, particularly the development of metabolic surgery. It evaluates different scoring systems for evidence-based selection of metabolic surgery based on disease severity. We reviewed different predictive scoring systems for better evidence-based selection of the best metabolic surgery for patients with diabesity. We found that medication type, fasting insulin level, and C-peptide influence the outcomes of different types of metabolic surgery and heterogeneous remission rates. There are different predictive scoring systems for evidence-based selection of the best metabolic surgery, either sleeve or mini-bypass, that will ensure the highest chance of diabetes remission. Using the metabolic score calculator is a useful tool to help medical specialists determine the optimal treatment strategy for a particular patient. More research is needed before we can agree on the ideal bariatric procedure that offers the highest chance of remission with the lowest incidence of hypoglycemia.
Chadt A, Scherneck S, Joost H-G, et al. Molecular links between obesity and diabetes: “Diabesity.” In: Endotext. South Dartmouth (MA):, Inc.; 2000.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50. PMid:28437734.
Richards SE, Wijeweera C, Wijeweera A. Lifestyle and socioeconomic determinants of diabetes: Evidence from country-level data. PloS ONE. 2022;17(7):e0270476. PMid:35901054 PMCid:PMC9333224.
Sims EA, Danforth Jr E, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973;29:457-96. PMid:4750591.
Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: Current concepts. World J Diabetes. 2023;14(4):396-411. PMid:37122433 PMCid:PMC10130896.
Kalra S. Diabesity. J Pak Med Assoc. 2013;63(4):532-4.
Ceriello A, Prattichizzo F. Variability of risk factors and diabetes complications. Cardiovasc Diabetol. 2021; 20(1):101. PMid:33962641 PMCid:PMC8106175.
Farag YMK, Gaballa MR. Diabesity: An overview of a rising epidemic. Nephrol Dial Transplant. 2011;26(1):28-35. PMid:21045078.
Al Asoom LI, Al Hariri MT. The association of adiposity, physical fitness, vitamin D levels and haemodynamic parameters in young Saudi females. J Taibah Univ Med Sci. 2018;13(1):51-7. PMid:31435302 PMCid:PMC6695083.
Al-Muzafar H, Al-Hariri M. Estimation of elemental concentrations in the toenail of young Saudi females with obesity. J Med Life. 2022;15(5):601-5. PMid:35815085 PMCid:PMC9262256.
Collins KK. The diabetes-cancer link. Diabetes Spectr. 2014; 27(4):276-80. PMid:25647050 PMCid:PMC4231938.
Al-Hariri M. Sweet bones: The pathogenesis of bone alteration in diabetes. J Diabetes Res. 2016;2016:6969040. PMid:27777961 PMCid:PMC5061963.
Muthiah M, Ng CH, Chan KE, et al. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: A longitudinal cohort analysis. Ann Hepatol. 2023; 28(1):100762. PMid:36182031.
Pappachan JM, Fernandez CJ, Chacko EC. Diabesity and antidiabetic drugs. Mol Aspects Med. 2019;66:3-12. PMid:30391234.
Buchwald H. The evolution of metabolic/bariatric surgery. Obes Surg. 2014;24(8):1126-35. PMid:25008469.
Field Jr RJ, Field 3rd RJ, Park SY. Vertical banded gastroplasty: Is obesity worth it? J Miss State Med Assoc. 1992;33(12):423-32.
Nih conference. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115(12):956-61.
Livhits M, Mercado C, Yermilov I, et al. Does weight loss immediately before bariatric surgery improve outcomes: A systematic review. Surg Obes Relat Dis. 2009;5(6):713-21. PMid:19879814.
Sundbom M. Laparoscopic revolution in bariatric surgery. World J Gastroenterol. 2014;20(41):15135-43. PMid:25386062 PMCid:PMC4223247.
Nguyen NT, Nguyen B, Gebhart A, Hohmann S. Changes in the makeup of bariatric surgery: A national increase in use of laparoscopic sleeve gastrectomy. J Am Coll Surg. 2013;216(2):252-7. PMid:23177371.
Gagner M, Hutchinson C, Rosenthal R. Fifth International Consensus Conference: Current status of sleeve gastrectomy. Surg Obes Relat Dis. 2016;12(4):750-6. PMid:27178618.
Wittgrove AC, Clark GW, Schubert KR. Laparoscopic gastric bypass, Roux en-Y: Technique and results in 75 patients with 3-30 months follow-up. Obes Surg. 1996;6(6):500-4. PMid:10729899.
De Luca M, Tie T, Ooi G, et al. Mini gastric bypass-one anastomosis gastric bypass (MGB-OAGB)-IFSO position statement. Obes Surg. 2018;28(5):1188-206. PMid:29600339.
Ghiassi S, Higa K, Chang S, et al. Conversion of standard Roux-en-Y gastric bypass to distal bypass for weight loss failure and metabolic syndrome: 3-year follow-up and evolution of technique to reduce nutritional complications. Surg Obes Relat Dis. 2018;14(5):554-61. PMid:29567059.
Varela JE, Wilson SE, Nguyen NT. Outcomes of bariatric surgery in the elderly. Am Surg. 2006;72(10):865-9. PMid:17058723.
Parikh MS, Shen R, Weiner M, Siegel N, Ren CJ. Laparoscopic bariatric surgery in super-obese patients (BMI>50) is safe and effective: A review of 332 patients. Obes Surg. 2005;15(6):858-63. PMid:15978159.
Younus H, Sharma A, Miquel R, et al. Bariatric surgery in cirrhotic patients: Is it safe? Obes Surg. 2020;30(4):1241-8. PMid:31853866.
Wikiel KJ, McCloskey CA, Ramanathan RC. Bariatric surgery: A safe and effective conduit to cardiac transplantation. Surg Obes Relat Dis. 2014;10(3):479-84. PMid:24462310.
Frankenfield DC, Rowe WA, Cooney RN, Smith JS, Becker D. Limits of body mass index to detect obesity and predict body composition. Nutrition. 2001;17(1):26-30. PMid:11165884.
Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297-304. PMid:24915261.
Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: State of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160-9. PMid:27899816.
Ponce J. 2013 ASMBS presidential address 30 years of accomplishments: Where do we go from here? Surg Obes Relat Dis. 2014;10(2):191-7. PMid:24679635.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes–5-year outcomes. N Engl J Med. 2017;376(7):641-51. PMid:28199805 PMCid:PMC5451258.
Rubino F, Kaplan LM, Schauer PR, Cummings DE, Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: Recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251(3):399-405. PMid:19934752.
Oh TJ, Lee H-J, Cho YM. East Asian perspectives in metabolic and bariatric surgery. J Diabetes Investig. 2022;13(5):756-61. PMid:35029061 PMCid:PMC9077716.
Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2023;18(12):1345-56. PMid:36280539.
Kamvissi V, Salerno A, Bornstein SR, Mingrone G, Rubino F. Incretins or anti-incretins? A new model for the “entero-pancreatic axis.” Horm Metab Res. 2015;47(1):84-7. PMid:25388925.
Kwon Y, Abdemur A, Menzo EL, Park S, Szomstein S, Rosenthal RJ. The foregut theory as a possible mechanism of action for the remission of type 2 diabetes in low body mass index patients undergoing subtotal gastrectomy for gastric cancer. Surg Obes Relat Dis. 2014;10(2):235-42. PMid:24496047.
Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: Evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005;48(11):2236-40. PMid:16195867.
Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;31(Suppl 2):S290-6. PMid:18227499.
Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010-3. PMid:17287468.
Wang W, Yu P-J, Lee Y-C, Wei P-L, Lee W-J. Laparoscopic vertical banded gastroplasty: 5-year results. Obes Surg. 2005;15(9):1299-303. PMid:16259891.
Arakawa R, Febres G, Cheng B, Krikhely A, Bessler M, Korner J. Prospective study of gut hormone and metabolic changes after laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass. PLoS One. 2020;15(7):e0236133. PMid:32687546 PMCid:PMC7371190.
Zorrilla-Nunez LF, Campbell A, Giambartolomei G, Menzo EL, Szomstein S, Rosenthal RJ. The importance of the biliopancreatic limb length in gastric bypass: A systematic review. Surg Obes Relat Dis. 2019;15(1):43-9. PMid:30501957.
Shen S-C, Wang W, Tam K-W, et al. Validating risk prediction models of diabetes remission after sleeve gastrectomy. Obes Surg. 2019;29(1):221-9. PMid:30251094.
Aminian A, Brethauer SA, Andalib A, et al. Individualized metabolic surgery score: Procedure selection based on diabetes severity. Ann Surg. 2017;266(4):650-7. PMid:28742680.
Dicker D, Golan R, Aron-Wisnewsky J, et al. Prediction of long-term diabetes remission after RYGB, sleeve gastrectomy, and adjustable gastric banding using DiaRem and advanced-DiaRem scores. Obes Surg. 2019;29(3):796-804. PMid:30467708.
Captieux M, Prigge R, Wild S, Guthrie B. Defining remission of type 2 diabetes in research studies: A systematic scoping review. PLoS Med. 2020;17(10):e1003396. PMid:33112845 PMCid:PMC7592769.
Singh P, Adderley NJ, Hazlehurst J, et al. Prognostic models for predicting remission of diabetes following bariatric surgery: A systematic review and meta-analysis. Diabetes Care. 2021;44(11):2626-41. PMid:34670787.
Lee MH, Lee W-J, Chong K, et al. Predictors of long-term diabetes remission after metabolic surgery. J Gastrointest Surg. 2015;19(6):1015-21. PMid:25840670.
Lee W-J, Almulaifi A, Tsou JJ, Ser K-H, Lee Y-C, Chen S-C. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus: Predicting the success by ABCD score. Surg Obes Relat Dis. 2015;11(5):991-6. PMid:25868836.
de Cleva R, Kawamoto F, Borges G, Caproni P, Cassenote AJF, Santo MA. C-peptide level as predictor of type 2 diabetes remission and body composition changes in non-diabetic and diabetic patients after Roux-en-Y gastric bypass. Clinics (Sao Paulo). 2021;76:e2906. PMid:34378729 PMCid:PMC8311643.
Aarts EO, Janssen J, Janssen IMC, Berends FJ, Telting D, de Boer H. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg. 2013;23(7):867-73. PMid:23475775.
Dixon JB, Chuang L-M, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36(1):20-6. PMid:23033249 PMCid:PMC3526207.
Yan W, Bai R, Yan M, Song M. Preoperative fasting plasma C-peptide levels as predictors of remission of type 2 diabetes mellitus after bariatric surgery: A systematic review and meta-analysis. J Invest Surg. 2017;30(6):383-93. PMid:28045566.
Park JY. Prediction of type 2 diabetes remission after bariatric or metabolic surgery. J Obes Metab Syndr. 2018; 27(4):213-22. PMid:31089566 PMCid:PMC6513303.
Aron-Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia. 2017;60(10):1892-902. PMid:28733906.
Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care. 2009;32(3):514-20. PMid:19246589 PMCid:PMC2646039.
Lee W-J, Chong K, Chen S-C, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: A comparison of DiaRem scores and ABCD scores. Obes Surg. 2016;26(10):2418-24. PMid:26932813.
Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: A retrospective cohort study. Lancet Diabetes Endocrinol. 2014;2(1):38-45. PMid:24579062.
Ahuja A, Tantia O, Chaudhuri T, et al. Predicting remission of diabetes post metabolic surgery: A comparison of ABCD, diarem, and DRS scores. Obes Surg. 2018;28(7):2025-31. PMid:29435812.
Eskandaros MS, Abbass A, Ebeid EF, Darwish AA. Remission of type II diabetes mellitus 1-year postoperative following one anastomosis gastric bypass in correlation with ABCD, DiaRem, and DRS scores. Obes Surg. 2022;32(2):450-6. PMid:34780027.
Blackstone R, Bunt JC, Cortés MC, Sugerman HJ. Type 2 diabetes after gastric bypass: Remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis. 2012;8(5):548-55. PMid:22721581.
Prasad M, Mark V, Ligon C, et al. Role of the gut in the temporal changes of β-cell function after gastric bypass in individuals with and without diabetes remission. Diabetes Care. 2022;45(2):469-76. PMid:34857533 PMCid:PMC8914419.
Wood GC, Horwitz D, Still CD, et al. Performance of the DiaRem score for predicting diabetes remission in two health systems following bariatric surgery procedures in Hispanic and non-Hispanic white patients. Obes Surg. 2018; 28(1):61-8. PMid:28717860 PMCid:PMC5736407.
Fatima F, Hjelmesæth J, Hertel JK, et al. Validation of ad-DiaRem and ABCD diabetes remission prediction scores at 1-year after Roux-en-Y gastric bypass and sleeve gastrectomy in the randomized controlled Oseberg trial. Obes Surg. 2022;32(3):801-9. PMid:34982397.
Saarinen I, Grönroos S, Hurme S, et al. Validation of the individualized metabolic surgery score for bariatric procedure selection in the merged data of two randomized clinical trials (SLEEVEPASS and SM-BOSS). Surg Obes Relat Dis. 2022;19(5):522-9. PMid:36503734.
Wilson R, Aminian A, Tahrani AA. Metabolic surgery: A clinical update. Diabetes Obes Metab. 2021;23 (Suppl 1):63-83. PMid:33621412.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med. 2009;122(3):248-56.e5. PMid:19272486.
Carlsson LMS, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695-704. PMid:22913680.
Sjöholm K, Carlsson LMS, Taube M, le Roux CW, Svensson P-A, Peltonen M. Comparison of preoperative remission scores and diabetes duration alone as predictors of durable type 2 diabetes remission and risk of diabetes complications after bariatric surgery: A post hoc analysis of participants from the Swedish obese subjects study. Diabetes Care. 2020;43(11):2804-11. PMid:32873586 PMCid:PMC7576422.
Journals System - logo
Scroll to top